Foundry BioSciences

About Foundry BioSciences

Foundry BioSciences is a biotechnology firm focused on extending human healthspan through the application of artificial intelligence in protein engineering. The company was co-founded by CEO Jingjing Chai and Kaiyi Jiang. Jingjing Chai is a Harvard alumnus with a decade of experience in deep-tech venture investments and technology transfer. Co-founder Kaiyi Jiang holds a PhD from MIT, was an inaugural Amgen Science Fellow, and is recognized in MIT Technology Review Asia's "35 Under 35". Their collective expertise in investment and life sciences forms the foundation of the company's strategy.

The core of Foundry BioSciences' operation is its AI-driven Protein Evolution Engine, which leverages protein language models and experimental validation to design and optimize proteins. This platform aims to address the molecular challenges of aging, such as cellular damage, protein dysfunction, and a weakening immune system. The company's technology is engineered to accelerate the discovery process, reducing protein engineering timelines from years to months. A key feature is the ability to generate proteins with significantly improved activity—reportedly 10 to 100 times greater than their natural counterparts.

The business model centers on providing computational services and developing healthspan-enhancing products. By creating proteins with superior properties, the firm targets the longevity and healthspan markets. The company's process involves iterative refinement guided by performance data and continuous improvements driven by experimental feedback cycles, a method designed to precisely address specific mechanisms of aging. This approach allows for the targeted design of proteins to combat age-related conditions.